The Meals and Drug Management on Friday stated it might rethink its resolution to take away Eli Lilly’s tirzepatide, bought as Mounjaro for diabetes and Zepbound for weight problems, from its scarcity listing, and, in the interim, would no longer pursue regulatory motion in opposition to sure compounding pharmacies making copies of the medicine.
The verdict, disclosed in a courtroom submitting, marked a stark reversal. Simply remaining week the company stated the years-long scarcity of the blockbuster drug had come to an finish. Underneath company tips, the FDA warned on the time, compounding pharmacies would now not be accredited to fabricate and dispense copies of the medicine.
Many compounders, telehealth firms, and sufferers temporarily objected to the FDA’s elimination of tirzepatide from the lack listing. The Outsourcing Amenities Affiliation, a gaggle that represents FDA-registered compounding pharmacies referred to as 503Bs, filed a lawsuit in opposition to the company on Monday in Texas, claiming the drug was once nonetheless in brief provide, and that company’s resolution was once “reckless and arbitrary.” It sought a brief restraining order for 14 days that may save you the FDA from taking motion in opposition to any compounder that continues making copies of the drug.
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Unencumber this text — plus day by day protection and research of the pharma business — by way of subscribing to STAT+.
Have already got an account? Log in
Particular person plans
Crew plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
